What is comparable to celebrex

1. O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591–2602. [PubMed] [Google Scholar]

2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094–1108. [PubMed] [Google Scholar]

3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis G . Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328–346. [PubMed] [Google Scholar]

4. Moore RA, Straube S, Aldington D. Pain measures and cut-offs – ‘no worse than mild pain’ as a simple, universal outcome. Anaesthesia 2013; 68: 400–412. [PubMed] [Google Scholar]

5. Andrew R, Derry S, Taylor RS, et al. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract 2014; 14: 79–94. [PubMed] [Google Scholar]

6. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12: 1–278, iii. [PubMed] [Google Scholar]

7. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–1255. [PubMed] [Google Scholar]

8. Fidahic M, Jelicic Kadic A, Radic M, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2017; 6: CD012095. [PMC free article] [PubMed] [Google Scholar]

9. Felson DT. Safety of nonsteroidal antiinflammatory drugs. N Engl J Med 2016; 375: 2595–2596. [PubMed] [Google Scholar]

10. Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728–738. [PubMed] [Google Scholar]

11. Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis–an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med 2015; 13: 55. [PMC free article] [PubMed] [Google Scholar]

12. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016; 45: S3–S11. [PubMed] [Google Scholar]

13. Colgan S, Faasse K, Martin LR, et al. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open 2015; 5: e008915. [PMC free article] [PubMed] [Google Scholar]

14. Faasse K, Martin LR, Grey A, et al. Impact of brand or generic labeling on medication effectiveness and side effects. Health Psychol 2016; 35: 187–190. [PubMed] [Google Scholar]

15. Panicheeva S, Ngsriwongse S, Mokkhavesa C, et al. Original versus generic piroxicams, their cost-effective evaluation in rheumatoid arthritis (RA) patients. J Med Assoc Thai 1992; 75: 104–109. [PubMed] [Google Scholar]

16. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheumat 2010; 62: 569–2581. [PubMed] [Google Scholar]

17. Song YW, Lee EY, Koh EM, et al. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. Clin Ther 2007; 29: 862–873. [PubMed] [Google Scholar]

18. Choi IA, Baek HJ, Cho CS, et al. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC Musculoskelet Disord 2014; 15: 375. [PMC free article] [PubMed] [Google Scholar]

19. Committee for Medicinal Products for Human U, Efficacy Working P and Committee for Release for C . Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med 2006; 25: 1628–1638. [PubMed] [Google Scholar]

20. Althunian TA, De Boer A, Groenwold RHH, et al. Defining the noninferiority margin and analysing noninferiority: an overview. Br J Clin Pharmacol 2017; 83: 1636–1642. [PMC free article] [PubMed] [Google Scholar]

21. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205–2219. [PubMed] [Google Scholar]

Are Celebrex and Naproxen the Same Thing?

Celebrex (celecoxib) and naproxen are nonsteroidal anti-inflammatory drugs (NSAIDs) used for the relief of pain, fever, swelling, and tenderness caused by arthritis, acute pain, and menstrual cramps.

Brand names for naproxen include Aleve, Naproxen, EC-Naproxen and Anaprox/Anaprox DS.

What Are Possible Side Effects of Celebrex?

Common side effects of Celebrex include:

• headache,
• abdominal pain,
• indigestion,
• diarrhea,
• nausea,
• upset stomach,
• bloating,
• gas,
• dizziness,
• nervousness,
• headache,
• runny or stuffy nose,
• sore throat,
• skin rash, and
• insomnia.

Celebrex may cause serious stomach and intestinal ulcers.

What Are Possible Side Effects of Naproxen?

Common side effects of Naproxen include:

• heartburn,
• stomach or abdominal pain,
• upset stomach,
• nausea,
• diarrhea,
• constipation,
• bloating,
• gas,
• dizziness,
• nervousness,
• skin rash,
• headache,
• blurred vision,
• ringing in your ears, and
• itching.

What is Celebrex?

Celebrex used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain.

What is Naproxen?

Naproxen is considered a nonsteroidal anti-inflammatory drug (NSAID) and is used for pain management for many diseases, arthritic diseases, and inflammatory diseases such as tendonitis, bursitis, and gout.